The contribution of chronic kidney disease to the global burden of major noncommunicable diseases

Kidney International

Volumn 81, Issue 10, 2012, Pages 1044-1045

  Woo, Keng Thye ^a   Choong, Hui L ^a   Wong, Kok Seng ^a   Tan, Hwee Boon ^a   Chan, Choong Meng ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CAUSAL ATTRIBUTION; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; DEVELOPING COUNTRY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; LETTER; LIFESTYLE MODIFICATION; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENOVASCULAR HYPERTENSION;

EID: 84860386107     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.39     Document Type: Letter

References (4)

1. Couser WG, Remuzzi G, Mendis S et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011; 80: 1258-1270.
2. Singapore Renal Registry. Seventh Report of the Singapore Renal Registry (2008). Health Promotion Board: Singapore, 2008, pp 14-15. ohttp://www.hpb.gov. sg/4
3. Suissa S, Hutchinson T, Brophy JM et al. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69: 913-919.
4. Wiggins KJ, Kelly DJ. Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors? Kidney Int 2009; 76: 23-31.